Pfizer’s Sutent Gains Conditional Approval In EU For GIST, Renal Cell Carcinoma
This article was originally published in The Pink Sheet Daily
Executive Summary
The company will submit Phase III data in August on sunitinib for RCC in order to gain full approval.
You may also be interested in...
Pfizer’s Sutent Gains First European Conditional Approval Recommendation
The firm may renew sunitinib’s conditional marketing authorization after one year or transition to a full license.
Pfizer's Sutent Receives Dual Approvals For Kidney Cancer & Stomach Cancer
Pfizer's Sutent received accelerated approval for first-line treatment of advanced renal cell carcinoma and full approval for treatment of refractory gastrointestinal stromal tumors.
Novartis Institute For Tropical Diseases Could Have TB Drug In Clinic By Late 2007
Singapore-based institute is also looking at dengue fever and malaria, exec says in interview with “The Pink Sheet” DAILY.